Back to Search
SHIRI NAWROCKI, MD
MD
Dermatology Physician
NPI: 1811512627IndividualAccepts Medicare
Specialties, Licenses & Credentials
Dermatology PhysicianPrimary
Dermatology
Code: 207N00000X
1018446(MA)
CMS Specialties
PrimaryDERMATOLOGY
Education
RUTGERS R W JOHNSON MEDICAL SCHOOL (CAM/NEW BRUNS/PISC)
Class of 2020
Research & Publications (20)
The Polish Cancer Anemia Survey (POLCAS): a retrospective multicenter study of 999 cases.
PMID 19343481·Int J Hematol·2009
4-observational
Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation.
PMID 19583815·J Cell Mol Med·2010
7-preclinical
Emerging drugs in the treatment of pancreatic cancer.
PMID 19466902·Expert Opin Emerg Drugs·2009
6-review
Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics.
PMID 18698017·Clin Cancer Res·2008
6-review
Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA.
PMID 18641367·Blood·2008
8-other
The novel polyamine analogue CGC-11093 enhances the antimyeloma activity of bortezomib.
PMID 18559525·Cancer Res·2008
7-preclinical
Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy.
PMID 18462867·Cancer Lett·2008
6-review
Clinical trials of active cancer immunotherapy.
PMID 17685864·Expert Opin Investig Drugs·2007
4-observational
Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels.
PMID 17638911·Cancer Res·2007
8-other
Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance.
PMID 17363733·Blood·2007
8-other
Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells.
PMID 16985059·Mol Cancer Ther·2006
7-preclinical
Src activation of Stat3 is an independent requirement from NF-kappaB activation for constitutive IL-8 expression in human pancreatic adenocarcinoma cells.
PMID 16871430·Angiogenesis·2006
8-other
Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.
PMID 16585204·Cancer Res·2006
7-preclinical
Targeting endoplasmic reticulum protein transport: a novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL.
PMID 16144803·Blood·2006
8-other
Using accumulated degree-days to estimate the postmortem interval from decomposed human remains.
PMID 15932096·J Forensic Sci·2005
8-other
Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis.
PMID 16357177·Cancer Res·2005
7-preclinical
Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells.
PMID 16357160·Cancer Res·2005
8-other
Prostaglandin E2 drives cyclooxygenase-2 expression via cyclic AMP response element activation in human pancreatic cancer cells.
PMID 16319525·Cancer Biol Ther·2005
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 441 STUART ST STE 404
BOSTON, MA 02116 - Phone
- (857) 317-2057
Quick Facts
- NPI
- 1811512627
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 6
- Publications
- 20
Are you this provider?
Claim Your Profile